Immune-related adverse events of checkpoint inhibitors
Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …
Advances in cancer immunotherapy 2019–latest trends
Immunotherapy has become an established pillar of cancer treatment improving the
prognosis of many patients with a broad variety of hematological and solid malignancies …
prognosis of many patients with a broad variety of hematological and solid malignancies …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …
cancers. While these immunotherapies have improved patient outcomes in many clinical …
Sex differences in immunity
Strong epidemiological evidence now exists that sex is an important biologic variable in
immunity. Recent studies, for example, have revealed that sex differences are associated …
immunity. Recent studies, for example, have revealed that sex differences are associated …
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
Following the success of immune checkpoint blockers (ICBs) in different cancer types, a
large number of studies are currently investigating ICBs in patients with hepatocellular …
large number of studies are currently investigating ICBs in patients with hepatocellular …
[HTML][HTML] Hepatocellular carcinoma in viral and autoimmune liver diseases: role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment
More than 90% of cases of hepatocellular carcinoma (HCC) occurs in patients with cirrhosis,
of which hepatitis B virus and hepatitis C virus are the leading causes, while the tumor less …
of which hepatitis B virus and hepatitis C virus are the leading causes, while the tumor less …
Advances in immunotherapy for colorectal cancer: a review
G Golshani, Y Zhang - Therapeutic advances in …, 2020 - journals.sagepub.com
Immunotherapy is a new and exciting modality of cancer treatments. Its role in
gastrointestinal malignancies has been promising, especially in advanced disease …
gastrointestinal malignancies has been promising, especially in advanced disease …
Profiling preexisting antibodies in patients treated with anti–PD-1 therapy for advanced non–small cell lung cancer
Y Toi, S Sugawara, J Sugisaka, H Ono… - JAMA …, 2019 - jamanetwork.com
Importance Administration of anti–programmed cell death protein 1 (anti–PD-1) is now
standard therapy in advanced non–small cell lung cancer (NSCLC). However, immune …
standard therapy in advanced non–small cell lung cancer (NSCLC). However, immune …
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of
advanced cancers. Designed to enhance the antitumour immune response, they can also …
advanced cancers. Designed to enhance the antitumour immune response, they can also …